Filing summary
Filing identity and period: The supplied filing is BioTime, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 14, 2012. The request names Lineage Cell Therapeutics, Inc.; that name does not appear as the registrant in the supplied filing. This is an annual report, not a standalone fourth-quarter filing, although unaudited Q4 data are included.
Business context and reporting period
BioTime was a biotechnology company focused primarily on regenerative medicine and stem-cell research products, with additional plasma-volume-expander royalties from Hextend. Its subsidiaries pursued cancer diagnostics and therapies, orthopedic and vascular treatments, retinal and neurological therapies, and a stem-cell database. Most therapeutic candidates remained in preclinical development; research products and Hextend royalties were nearer-term revenue sources.
Financial performance and position
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Total revenue | $4.35 million | $3.68 million |
| Research and development expense | $13.70 million | $8.19 million |
| General and administrative expense | $9.34 million | $5.34 million |
| Operating loss | $18.69 million | $9.85 million |
| Net loss | $18.44 million | $12.19 million |
| Net loss attributable to BioTime | $16.52 million | $11.18 million |
| Comprehensive loss | $17.54 million | $10.29 million |
| Basic and diluted loss per share | $0.35 | $0.28 |
| Cash and cash equivalents at year-end | $22.21 million | $33.32 million |
- Revenue increased 18.3%, led by grant income and research-product sales. Grant income was $2.77 million; research-product sales were $0.57 million. Hextend royalties were $0.76 million, down from $0.95 million.
- Operating expenses rose 70.3%; R&D increased 67.3% and G&A increased 74.9%. The filing attributes increases in part to acquired businesses, expanded staffing and research activity, and amortization of acquired intangible assets.
- Net cash used in operating activities was $13.59 million; investing activities used $1.20 million; financing activities provided $3.86 million. Cash declined by $11.11 million during the year.
- Year-end current assets were $24.96 million and current liabilities were $3.15 million. Total assets were $45.83 million; total equity was $41.46 million. Long-term liabilities were $1.22 million, including deferred revenue, deferred rent, and other liabilities. The filing does not clearly present a separate year-end debt balance; it reports no 2011 borrowing proceeds or repayments.
- There was no meaningful positive operating margin: the company reported a substantial operating loss. The filing does not provide a useful positive profit margin.
- Unaudited Q4 2011 results: revenue $1.63 million, operating expenses $7.08 million, operating loss $5.45 million, net loss attributable to BioTime $5.14 million, and loss per share $0.10.
Material changes versus the prior period
- Revenue grew, but operating losses widened as expenses expanded faster than revenue. R&D spending rose from $8.19 million to $13.70 million.
- Hextend royalties weakened amid lower hetastarch prices and a shrinking market; hospitals shifted purchases toward albumin. Hospira implemented further Hextend price reductions in 2012.
- Research-product sales rose from $0.11 million to $0.57 million, but remained small relative to operating costs.
- Cash fell from $33.32 million to $22.21 million, despite $3.21 million of proceeds from subsidiary share sales and other financing receipts.
- BioTime acquired Cell Targeting assets and Glycosan in 2011, adding cancer-targeting technology and the HyStem hydrogel business. It also formed LifeMap Sciences and increased its investment in OncoCyte.
Outlook, management commentary, and risks
- Management said it might need additional debt or equity financing; failure to obtain capital or generate adequate revenue could force programs to be modified, delayed, or suspended. The filing provides no firm cash-runway estimate.
- Management stated that subsidiaries had sufficient capital for their then-current 2012 research plans, but BioTime could provide further financing depending on progress, program scope, and projected costs.
- HyStem-Rx had completed biocompatibility testing. The company targeted clinical-lot manufacture and an ISO certification audit by mid-2012, with EU clinical trials targeted for late 2012. These were plans, not assured outcomes.
- PanC-Dx was a development-stage blood-based cancer-screening test. The filing describes a planned European launch in 2014 in one section, while another discusses a 2013 target; the timing is therefore not consistent across the filing. U.S. marketing would require further regulatory approval.
- Key risks include clinical and regulatory failure, substantial development costs, dependence on outside licensees and collaborators, reliance on grants and Hextend royalties, competition, intellectual-property disputes, and potential dilution from future financing and subsidiary equity issuance.
- The company reported no material litigation and no off-balance-sheet arrangements. The independent auditor gave an unqualified opinion on the financial statements and concluded that internal control over financial reporting was effective as of December 31, 2011.
Most important facts for investors to verify
- Confirm the registrant’s identity: the supplied 10-K is for BioTime, Inc., not Lineage Cell Therapeutics, Inc.
- Check subsequent filings for actual cash use, financing, and whether the stated 2012 funding needs were met.
- Track Hextend sales, pricing, and royalties, given the reported market contraction and customer concentration.
- Verify actual regulatory and clinical progress for HyStem-Rx and PanC-Dx, including the conflicting PanC-Dx launch timing.
- Review the financial-statement notes for acquisition-related intangible assets and amortization, subsidiary ownership and dilution, and the terms of material licenses and collaborations.
- Assess the extent to which reported revenue depends on grants: grants were $2.77 million of FY 2011 revenue, while product royalties and research-product sales remained limited.